OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]
OnKure Therapeutics, Inc. - Class A (OKUR)
Company Research
Source: Seeking Alpha
Terry Chrisomalis Investing Group Leader Follow Summary Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026. Significant market opportunity exists with 15% of breast cancer patients expressing the PI3Ka-H1047R mutation, and the company aims to outperform competitors with greater selectivity of OKI-219. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » miodrag ignjatovic/E+ via Getty Images OnKure Therapeutics, Inc. NASDAQ
Show less
Read more
Impact Snapshot
Event Time:
OKUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKUR alerts
High impacting OnKure Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
OKUR
News
- OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 [Yahoo! Finance]Yahoo! Finance
- OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219GlobeNewswire
- OnKure Therapeutics (NASDAQ: OKUR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- OnKure Therapeutics (NASDAQ: OKUR) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.MarketBeat
- OnKure Announces New Date for Upcoming Investor Call [Yahoo! Finance]Yahoo! Finance
OKUR
Sec Filings
- 12/10/24 - Form 424B3
- 12/10/24 - Form 8-K
- 12/9/24 - Form S-8
- OKUR's page on the SEC website